Microfluidic co-culture of pancreatic tumor spheroids with stellate cells as a novel 3D model for investigation of stroma-mediated cell motility and drug resistance

Journal of Experimental and Clinical Cancer Research

Volumn 37, Issue 1, 2018, Pages

  Lee, Ji Hyun ^a   Kim, Seul Ki ^a   Khawar, Iftikhar Ali ^a   Jeong, Su Yeong ^a   Chung, Seok ^b   Kuh, Hyo Jeong ^a  

^a The Catholic University of Korea   (South Korea)

^b Korea University   (South Korea)

Author keywords

Cancer Stroma co culture; EMT; Microchannel plate; Pancreatic cancer; Tumor microenvironment

Indexed keywords

BIOLOGICAL MARKER; COLLAGEN TYPE 1; DIMETICONE; GEMCITABINE; INTERLEUKIN 8; PACLITAXEL; PROTEOME; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; VIMENTIN;

ARTICLE; ASSAY; CANCER GROWTH; CANCER RESISTANCE; CELL ACTIVATION; CELL CULTURE; CELL CULTURE MONITORING; CELL INTERACTION; CELL MIGRATION; CELL MOTILITY; CELL VIABILITY; COCULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EXPOSURE; DRUG RESPONSE ASSAY; DRUG SENSITIVITY; EPITHELIAL MESENCHYMAL TRANSITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VIVO STUDY; LIVE DEAD ASSAY; MICROCHIP ANALYSIS; MICROFLUIDIC ANALYSIS; MICROTECHNOLOGY; MODULATION; MOLECULAR BIOLOGY; PANC-1 CELL LINE; PANCREAS TUMOR; PANCREATIC STELLATE CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEOMICS; SURVIVAL; TUMOR MICROENVIRONMENT; TUMOR SPHEROID; CELL MOTION; DRUG RESISTANCE; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; METABOLISM; MICROFLUIDICS; MOLECULAR IMAGING; PATHOLOGY; PROCEDURES; STROMA CELL; TUMOR CELL LINE;

BIOMARKERS; CELL LINE, TUMOR; CELL MOVEMENT; COCULTURE TECHNIQUES; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MICROFLUIDICS; MOLECULAR IMAGING; PANCREATIC NEOPLASMS; PANCREATIC STELLATE CELLS; STROMAL CELLS; TUMOR MICROENVIRONMENT;

EID: 85040455387     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/s13046-017-0654-6     Document Type: Article

References (64)

1. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362(17):1605-17.
2. Von Hoff DD, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011;29(34):4548-54.
3. Drifka CR, et al. A bioengineered heterotypic stroma-cancer microenvironment model to study pancreatic ductal adenocarcinoma. Lab Chip. 2013;13(19):3965-75.
4. Feig C, et al. The pancreas cancer microenvironment. Clin Cancer Res. 2012;18(16):4266-76.
5. Apte MV, Pirola RC, Wilson JS. Pancreatic stellate cells: a starring role in normal and diseased pancreas. Front Physiol. 2012;3:344.
6. Erkan M, et al. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol. 2012;9(8):454-67.
7. Armstrong T, et al. Type I collagen promotes the malignant phenotype of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2004;10(21):7427-37.
8. Duner S, et al. Pancreatic cancer: the role of pancreatic stellate cells in tumor progression. Pancreatology. 2010;10(6):673-81.
9. Shields MA, et al. Biochemical role of the collagen-rich tumour microenvironment in pancreatic cancer progression. Biochem J. 2012;441(2):541-52.
10. McCarroll JA, et al. Role of pancreatic stellate cells in chemoresistance in pancreatic cancer. Front Physiol. 2014;5:141.
11. Erkan M, et al. The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol. 2008;6(10):1155-61.
12. Hingorani SR, et al. Phase Ib study of PEGylated recombinant human Hyaluronidase and gemcitabine in patients with advanced pancreatic cancer. Clin Cancer Res. 2016;22(12):2848-54.
13. Ohlund D, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017;214(3):579-96.
14. Kawase T, et al. Fibroblast activation protein-alpha-expressing fibroblasts promote the progression of pancreatic ductal adenocarcinoma. BMC Gastroenterol. 2015;15:109.
15. van Zijl F, et al. Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge. Oncogene. 2009;28(45):4022-33.
16. Arumugam T, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009;69(14):5820-8.
17. Voulgari A, Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta. 2009;1796(2):75-90.
18. Baril P, et al. Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3k pathway. Oncogene. 2007;26(14):2082-94.
19. Wang Z, et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009;69(6):2400-7.
20. Fennema E, et al. Spheroid culture as a tool for creating 3D complex tissues. Trends Biotechnol. 2013;31(2):108-15.
21. Hickman JA, et al. Three-dimensional models of cancer for pharmacology and cancer cell biology: capturing tumor complexity in vitro/ex vivo. Biotechnol J. 2014;9(9):1115-28.
22. Joshi P, Lee MY. High content imaging (HCI) on miniaturized three-dimensional (3D) cell cultures. Biosensors (Basel). 2015;5(4):768-90.
23. Young EW. Cells, tissues, and organs on chips: challenges and opportunities for the cancer tumor microenvironment. Integr Biol (Camb). 2013;5(9):1096-109.
24. Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32(8):760-72.
25. van Duinen V, et al. Microfluidic 3D cell culture: from tools to tissue models. Curr Opin Biotechnol. 2015;35:118-26.
26. An D, Kim K, Kim J. Microfluidic system based high throughput drug screening system for Curcumin/TRAIL combinational chemotherapy in human prostate cancer PC3 cells. Biomol Ther (Seoul). 2014;22(4):355-62.
27. Bersini S, et al. A microfluidic 3D in vitro model for specificity of breast cancer metastasis to bone. Biomaterials. 2014;35(8):2454-61.
28. Jeong SY, et al. Co-culture of tumor spheroids and fibroblasts in a collagen matrix-incorporated microfluidic Chip mimics reciprocal activation in solid tumor microenvironment. PLoS One. 2016;11(7):e0159013.
29. Shin Y, et al. Microfluidic assay for simultaneous culture of multiple cell types on surfaces or within hydrogels. Nat Protoc. 2012;7(7):1247-59.
30. Chuah YJ, et al. Simple surface engineering of polydimethylsiloxane with polydopamine for stabilized mesenchymal stem cell adhesion and multipotency. Sci Rep. 2015;5:18162.
31. Fujiwara M, et al. ASF-4-1 fibroblast-rich culture increases chemoresistance and mTOR expression of pancreatic cancer BxPC-3 cells at the invasive front in vitro, and promotes tumor growth and invasion in vivo. Oncol Lett. 2016;11(4):2773-9.
32. Kim SA, Lee EK, Kuh HJ. Co-culture of 3D tumor spheroids with fibroblasts as a model for epithelial-mesenchymal transition in vitro. Exp Cell Res. 2015;335(2):187-96.
33. Kang J, et al. Mini-pillar array for hydrogel-supported 3D culture and high-content histologic analysis of human tumor spheroids. Lab Chip. 2016;16(12):2265-76.
34. Matsuda Y, et al. Morphological and cytoskeletal changes of pancreatic cancer cells in three-dimensional spheroidal culture. Med Mol Morphol. 2010;43(4):211-7.
35. Ware MJ, et al. Generation of homogenous three-dimensional pancreatic cancer cell spheroids using an improved hanging drop technique. Tissue Eng Part C Methods. 2016;22(4):312-21.
36. Yeon SE, et al. Application of concave microwells to pancreatic tumor spheroids enabling anticancer drug evaluation in a clinically relevant drug resistance model. PLoS One. 2013;8(9):e73345.
37. Habisch H, et al. Interaction of stellate cells with pancreatic carcinoma cells. Cancers (Basel). 2010;2(3):1661-82.
38. Wehr AY, et al. Analysis of the human pancreatic stellate cell secreted proteome. Pancreas. 2011;40(4):557-66.
39. Ghersi G, et al. Regulation of fibroblast migration on collagenous matrix by a cell surface peptidase complex. J Biol Chem. 2002;277(32):29231-41.
40. Kim SA, et al. Indirect modulation of sensitivity to 5-fluorouracil by microRNA-96 in human colorectal cancer cells. Arch Pharm Res. 2015;38(2):239-48.
41. Fan X, et al. Isolation and characterization of spheroid cells from the HT29 colon cancer cell line. Int J Color Dis. 2011;26(10):1279-85.
42. Song Y, et al. TGF-beta-independent CTGF induction regulates cell adhesion mediated drug resistance by increasing collagen I in HCC. Oncotarget. 2017;8(13):21650-62.
43. Sandbo N, et al. Control of myofibroblast differentiation by microtubule dynamics through a regulated localization of mDia2. J Biol Chem. 2013;288(22):15466-73.
44. Ikenaga N, et al. Pancreatic cancer cells enhance the ability of collagen internalization during epithelial-mesenchymal transition. PLoS One. 2012;7(7):e40434.
45. Ikushima H, Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer. 2010;10(6):415-24.
46. Dornhofer N, et al. Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis. Cancer Res. 2006;66(11):5816-27.
47. Loomans HA, Andl CD. Intertwining of Activin a and TGFbeta signaling: dual roles in cancer progression and cancer cell invasion. Cancers (Basel). 2014;7(1):70-91.
48. Lonardo E, et al. Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell. 2011;9(5):433-46.
49. Fernando RI, et al. IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Res. 2011;71(15):5296-306.
50. Han X, et al. Tissue factor in tumor microenvironment: a systematic review. J Hematol Oncol. 2014;7:54.
51. Pavon MA, et al. uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy. Oncotarget. 2016;7(35):57351-66.
52. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002;3(12):932-43.
53. Jackson HW, et al. TIMPs: versatile extracellular regulators in cancer. Nat Rev Cancer. 2017;17(1):38-53.
54. Li C, et al. Overexpression of angiopoietin 2 promotes the formation of oral squamous cell carcinoma by increasing epithelial-mesenchymal transition-induced angiogenesis. Cancer Gene Ther. 2016;23(9):295-302.
55. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178-96.
56. Kantola T, et al. Serum endostatin levels are elevated in colorectal cancer and correlate with invasion and systemic inflammatory markers. Br J Cancer. 2014;111(8):1605-13.
57. Carvalhaes LS, et al. Collagen XVIII/endostatin is associated with the epithelial-mesenchymal transformation in the atrioventricular valves during cardiac development. Dev Dyn. 2006;235(1):132-42.
58. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420-8.
59. Fischer KR, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. 2015;527(7579):472-6.
60. Alvarez R, et al. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br J Cancer. 2013;109(4):926-33.
61. Neesse A, et al. SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice. Gut. 2014;63(6):974-83.
62. Cullis J, et al. Macropinocytosis of nab-paclitaxel drives macrophage activation in pancreatic cancer. Cancer Immunol Res. 2017;5(3):182-90.
63. Danowski BA. Fibroblast contractility and actin organization are stimulated by microtubule inhibitors. J Cell Sci. 1989;93(Pt 2):255-66.
64. Green KJ, Goldman RD. The effects of taxol on cytoskeletal components in cultured fibroblasts and epithelial cells. Cell Motil. 1983;3(4):283-305.